logo

Middle East and Africa Diabetes Drugs Market Size (2024 - 2029)

The Middle East and Africa diabetes drugs market is projected to experience growth over the forecast period, driven by an increasing prevalence of diabetes in the region. The COVID-19 pandemic highlighted the vulnerability of diabetes patients, as they faced heightened risks due to weakened immune systems. This situation underscored the importance of diabetic drugs, which are essential for managing blood glucose levels and mitigating complications. The market's expansion is further supported by the rising number of individuals diagnosed with diabetes and impaired glucose tolerance, necessitating effective treatment solutions.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Diabetes Care Drugs Research MEA Diabetes Drugs Treatment Market Market Size

Market Size of Middle East and Africa Diabetes Drugs Industry

MEA Diabetes Drugs Market Summary
Study Period 2018 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2018 - 2022
CAGR 5.97 %

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

Middle East and Africa Diabetes Treatment Market Analysis

The Middle East and Africa Diabetes Drugs Market size is estimated at USD 4.57 billion in 2023 and is expected to reach USD 6.10 billion by 2028, growing at a CAGR of 5.97% during the forecast period (2023-2028).

The COVID-19 pandemic positively impacted the Middle East and African diabetes drugs market. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19, including an increased risk of severe illness or death. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. People with diabetes have more chances of getting into serious complications than normal people.

Diabetic drugs are medicines developed to stabilize and control blood glucose levels among people with diabetes. Diabetic drugs are commonly used to manage diabetes. Diabetic drugs have been potential candidates for treating diabetic patients affected by SARS-CoV-2 infection during the COVID-19 pandemic. Seventy-three million adults (20-79) were living with diabetes in the IDF MENA Region in 2021. This figure is estimated to increase to 95 million by 2030. Forty-eight million adults in the IDF MENA Region live with impaired glucose tolerance, increasing their risk of developing type 2 diabetes. Diabetes was responsible for 796,000 deaths in the IDF MENA Region in 2021. USD 33 billion was spent on healthcare for people with diabetes in 2021.

The Middle East and African regions witnessed an alarming increase in the prevalence of diabetes in recent years. The rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Patients with diabetes require many daily corrections to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels.

Therefore, owing to the factors mentioned above, the studied market is anticipated to witness growth over the analysis period.

Middle East and Africa Diabetes Treatment Industry Segmentation

Diabetes Drugs are used to manage diabetes mellitus by lowering the glucose level in the blood. The Middle East and Africa Diabetes Drugs Market is segmented into drugs (Insulin, Oral anti-diabetic drugs, Non-Insulin Injectable drugs, and Combination Drugs) and Geography (Saudi Arabia, Iran, Egypt, Oman, South Africa, and the rest of the Middle East and Africa). The report offers the value (in USD) and volume (in Units) for the above segments. Further, the report will cover a segment-wise breakdown (Value and Volume) for all the countries covered under the Table of Contents.

Oral Anti-diabetic Drugs
Biguanides
Metformin
Alpha - Glucosidase Inhibitors
Alpha - Glucosidase Inhibitors
Dopamine -D2 Receptor Agonist
Bromocriptin (Cycloset)
Sodium-glucose Cotransport -2 (SGLT-2) Inhibitor
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Sulfonylureas
Meglitinides
Meglitinides
Insulins
Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humulin
Insuman
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Combination drugs
Insulin combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combinations
Janumet (Sitagliptin and Metformin)
Non-Insulin Injectable drugs
GLP-1 receptor agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue
Symlin (Pramlintide)
Geography
Saudi Arabia
Iran
Egypt
Oman
South Africa
Rest of Middle East and Africa
Need A Different Region Or Segment?
Customize Now

Middle East and Africa Diabetes Drugs Market Size Summary

The Middle East and Africa diabetes drugs market is experiencing significant growth, driven by the rising prevalence of diabetes and the increasing demand for effective treatment options. The market is characterized by a shift towards oral anti-diabetic drugs, which are preferred due to their ease of use, cost-effectiveness, and ability to manage blood glucose levels effectively. The COVID-19 pandemic has further highlighted the importance of diabetes management, as individuals with diabetes are at a higher risk of severe complications from the virus. This has led to an increased focus on developing and distributing diabetic drugs that can help stabilize blood sugar levels and improve patient outcomes. The market is moderately fragmented, with major players like Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca actively participating and introducing innovative solutions to cater to the growing demand.

Saudi Arabia holds a significant share of the market, with a high prevalence of diabetes and a strong focus on healthcare initiatives to address the issue. The government and private sector are collaborating to enhance healthcare services, ensuring affordability, access, and quality care for diabetic patients. The introduction of new drug classes, such as DPP-4 and SGLT-2 inhibitors, has expanded treatment options, while ongoing innovations in drug formulation and technology continue to drive market growth. The presence of major manufacturers and strategic partnerships in the region is expected to maintain a competitive landscape, encouraging further advancements and expansion in the diabetes drugs market over the forecast period.

Explore More

Middle East and Africa Diabetes Drugs Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Oral Anti-diabetic Drugs

      1. 2.1.1 Biguanides

        1. 2.1.1.1 Metformin

      2. 2.1.2 Alpha - Glucosidase Inhibitors

        1. 2.1.2.1 Alpha - Glucosidase Inhibitors

      3. 2.1.3 Dopamine -D2 Receptor Agonist

        1. 2.1.3.1 Bromocriptin (Cycloset)

      4. 2.1.4 Sodium-glucose Cotransport -2 (SGLT-2) Inhibitor

        1. 2.1.4.1 Invokana (Canagliflozin)

        2. 2.1.4.2 Jardiance (Empagliflozin)

        3. 2.1.4.3 Farxiga/Forxiga (Dapagliflozin)

        4. 2.1.4.4 Suglat (Ipragliflozin)

      5. 2.1.5 Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors

        1. 2.1.5.1 Januvia (Sitagliptin)

        2. 2.1.5.2 Onglyza (Saxagliptin)

        3. 2.1.5.3 Tradjenta (Linagliptin)

        4. 2.1.5.4 Vipidia/Nesina (Alogliptin)

        5. 2.1.5.5 Galvus (Vildagliptin)

      6. 2.1.6 Sulfonylureas

        1. 2.1.6.1 Sulfonylureas

      7. 2.1.7 Meglitinides

        1. 2.1.7.1 Meglitinides

    2. 2.2 Insulins

      1. 2.2.1 Basal or Long Acting Insulins

        1. 2.2.1.1 Lantus (Insulin Glargine)

        2. 2.2.1.2 Levemir (Insulin Detemir)

        3. 2.2.1.3 Toujeo (Insulin Glargine)

        4. 2.2.1.4 Tresiba (Insulin Degludec)

        5. 2.2.1.5 Basaglar (Insulin Glargine)

      2. 2.2.2 Bolus or Fast Acting Insulins

        1. 2.2.2.1 NovoRapid/Novolog (Insulin Aspart)

        2. 2.2.2.2 Humalog (Insulin Lispro)

        3. 2.2.2.3 Apidra (Insulin Glulisine)

      3. 2.2.3 Traditional Human Insulins

        1. 2.2.3.1 Novolin/Actrapid/Insulatard

        2. 2.2.3.2 Humulin

        3. 2.2.3.3 Insuman

      4. 2.2.4 Biosimilar Insulins

        1. 2.2.4.1 Insulin Glargine Biosimilars

        2. 2.2.4.2 Human Insulin Biosimilars

    3. 2.3 Combination drugs

      1. 2.3.1 Insulin combinations

        1. 2.3.1.1 NovoMix (Biphasic Insulin Aspart)

        2. 2.3.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

        3. 2.3.1.3 Xultophy (Insulin Degludec and Liraglutide)

      2. 2.3.2 Oral Combinations

        1. 2.3.2.1 Janumet (Sitagliptin and Metformin)

    4. 2.4 Non-Insulin Injectable drugs

      1. 2.4.1 GLP-1 receptor agonists

        1. 2.4.1.1 Victoza (Liraglutide)

        2. 2.4.1.2 Byetta (Exenatide)

        3. 2.4.1.3 Bydureon (Exenatide)

        4. 2.4.1.4 Trulicity (Dulaglutide)

        5. 2.4.1.5 Lyxumia (Lixisenatide)

      2. 2.4.2 Amylin Analogue

        1. 2.4.2.1 Symlin (Pramlintide)

    5. 2.5 Geography

      1. 2.5.1 Saudi Arabia

      2. 2.5.2 Iran

      3. 2.5.3 Egypt

      4. 2.5.4 Oman

      5. 2.5.5 South Africa

      6. 2.5.6 Rest of Middle East and Africa

Middle East and Africa Diabetes Drugs Market Size FAQs

The MEA Diabetes Drugs Market is projected to register a CAGR of 5.97% during the forecast period (2024-2029)

Boehringer Ingelheim, Astrazeneca, Eli Lilly, Sanofi and Novo Nordisk are the major companies operating in the MEA Diabetes Drugs Market.

Middle East and Africa Diabetes Drugs Treatment Market Report Snapshots

Middle East and Africa Diabetes Drugs Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)